A slew of start-ups and academic labs are leaning on AI agents and bots, rather than humans, to speed up their chemistry ...

Among over 400 people with eating disorders in an interim analysis of an ongoing cross-sectional study, 32.1% said they have used GLP-1 drugs, and 22% reported current use. Overall, 10% said they have ...

For those scared of needles but who need GLP-1 receptor agonists to help manage their weight, there might be some good news. Researchers are testing a new oral, small-molecule GLP-1 receptor agonist ...

Adults aged 65 and older who took semaglutide 2.4 mg lost an average of 15.4% of their body weight over 68 weeks, according ...

Many pains encountered in palliative care result from multiple pain mechanisms, eg, cancer pain may include inflammatory, bony, neuropathic, myofascial and/or visceral components. Not all such pains ...

GLP-1 microdosing is when people take smaller doses of GLP-1 drugs than are typically prescribed or FDA-recommended, often ...

Pangea Pharmaceuticals, a U.S.-based, patient-centered pharmaceutical company focused on bringing differentiated, clinically relevant products to market, today announced the next phase of its growth ...

Polypharmacy in patients with cardiovascular disease occurs frequently across the age spectrum and can lead to inappropriate prescribing and adverse outcomes. Despite polypharmacy being a known ...

Background Irritable bowel syndrome with diarrhoea (IBS-D) is particularly debilitating due to urgency and episodic incontinence. Some 5-hydroxytryptamine 3 (5-HT3) receptor antagonists (5-HT3RAs) ...